{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T11:21:16Z","timestamp":1784373676805,"version":"3.55.0"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001026","name":"National Breast Cancer Foundation","doi-asserted-by":"publisher","award":["IIRS21-066"],"award-info":[{"award-number":["IIRS21-066"]}],"id":[{"id":"10.13039\/501100001026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001026","name":"National Breast Cancer Foundation","doi-asserted-by":"publisher","award":["ECF17-002"],"award-info":[{"award-number":["ECF17-002"]}],"id":[{"id":"10.13039\/501100001026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1138077"],"award-info":[{"award-number":["APP1138077"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The estrogen receptor (ER) drives growth in most breast cancers. Endocrine therapy reduces recurrence, however around 30% of cancers relapse. Many recurrences occur years later, with slowly proliferating, hard-to-treat disease. To study this, we generate slow-growing resistant cells that form small primary tumours but readily metastasise. Single-cell RNA sequencing (scRNAseq) reveals that endocrine therapy reprograms these cells, notably upregulating the Rac1 signalling component P-Rex1. We find in clinical cohorts that P-Rex1 is high in ER+ breast cancer, including in late recurrent disease. Intravital imaging demonstrates that Rac1 signalling is active in ER+ cells following endocrine therapy. Targeting the Rac1 pathway with small molecule inhibitors (NSC23766, R-ketorolac) reduces survival and motility in resistant cells, inhibits in vivo Rac1 activity, and reduces tumour burden when combined with tamoxifen in a drug-refractory patient derived xenograft model. This work identifies the P-Rex1\/Rac1 axis as a potential therapeutic target for late recurring ER+ breast cancer.<\/jats:p>","DOI":"10.1038\/s41467-026-70683-x","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T09:11:28Z","timestamp":1778490688000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1\/Rac1 signalling"],"prefix":"10.1038","volume":"17","author":[{"given":"Kristine J.","family":"Fernandez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazal","family":"Sultani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1861-1390","authenticated-orcid":false,"given":"Max","family":"Nobis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Gloss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Eshraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5387-2791","authenticated-orcid":false,"given":"Amy E.","family":"McCart Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1186-6507","authenticated-orcid":false,"given":"Sarah","family":"Alexandrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily I.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam Hasha","family":"Simad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewan K. A.","family":"Millar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nenad","family":"Bartonicek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha R.","family":"Oakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7490-0114","authenticated-orcid":false,"given":"Fatima","family":"Valdes-Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Colino-Sanguino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7750-3335","authenticated-orcid":false,"given":"Ellie T. Y.","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0434-3900","authenticated-orcid":false,"given":"Hannah L.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie R.","family":"Kutasovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret C.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4198-3520","authenticated-orcid":false,"given":"Janett","family":"Stoehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2155-5203","authenticated-orcid":false,"given":"Kate","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6153-0449","authenticated-orcid":false,"given":"Sunny","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1879-2555","authenticated-orcid":false,"given":"Sunil R.","family":"Lakhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4816-8289","authenticated-orcid":false,"given":"Peter T.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9294-1745","authenticated-orcid":false,"given":"Thomas R.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8918-9932","authenticated-orcid":false,"given":"Lisa M.","family":"Ooms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9372-3192","authenticated-orcid":false,"given":"Christina A.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4504-2901","authenticated-orcid":false,"given":"Rob","family":"Salomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3051-5676","authenticated-orcid":false,"given":"Alexander","family":"Swarbrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2347-7835","authenticated-orcid":false,"given":"David","family":"Gallego-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8065-8838","authenticated-orcid":false,"given":"Elgene","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5514-7080","authenticated-orcid":false,"given":"Paul","family":"Timpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1392-3472","authenticated-orcid":false,"given":"C. Elizabeth","family":"Caldon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"70683_CR1","doi-asserted-by":"publisher","first-page":"6389","DOI":"10.1158\/1078-0432.CCR-13-0838","volume":"19","author":"XH-F Zhang","year":"2013","unstructured":"Zhang, X. H.-F., Giuliano, M., Trivedi, M. V., Schiff, R. & Osborne, C. K. Metastasis Dormancy in Estrogen Receptor\u2013Positive Breast Cancer. Clin. Cancer Res. 19, 6389\u20136397 (2013).","journal-title":"Clin. Cancer Res."},{"key":"70683_CR2","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/bjc.2011.402","volume":"105","author":"S Sahebjam","year":"2011","unstructured":"Sahebjam, S. et al. Ki 67 is a major, but not the sole determinant of oncotype Dx recurrence score. Br. J. Cancer 105, 1342\u20131345 (2011).","journal-title":"Br. J. Cancer"},{"key":"70683_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0514-2","volume":"17","author":"B Gy\u0151rffy","year":"2015","unstructured":"Gy\u0151rffy, B. et al. Multigene prognostic tests in breast cancer: past, present, future. Breast Cancer Res. 17, 11 (2015).","journal-title":"Breast Cancer Res."},{"key":"70683_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-016-0988-0","volume":"14","author":"P Wangchinda","year":"2016","unstructured":"Wangchinda, P. & Ithimakin, S. Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer. World J. Surg. Oncol. 14, 223 (2016).","journal-title":"World J. Surg. Oncol."},{"key":"70683_CR5","doi-asserted-by":"crossref","unstructured":"Gomis, R. R. & Gawrzak, S. Tumor cell dormancy. Mol. Oncol. 11, 62\u201378 (2017).","DOI":"10.1016\/j.molonc.2016.09.009"},{"key":"70683_CR6","first-page":"688","volume":"26","author":"E Lim","year":"2012","unstructured":"Lim, E., Metzger-Filho, O. & Winer, E. P. The natural history of hormone receptor-positive breast cancer. Oncology 26, 688\u2013694 (2012).","journal-title":"Oncology"},{"key":"70683_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41416-020-01161-4","volume":"124","author":"AI Riggio","year":"2021","unstructured":"Riggio, A. I., Varley, K. E. & Welm, A. L. The lingering mysteries of metastatic recurrence in breast cancer. Br. J. Cancer 124, 13\u201326 (2021).","journal-title":"Br. J. Cancer"},{"key":"70683_CR8","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1158\/1055-9965.EPI-12-0043","volume":"21","author":"RJ Santen","year":"2012","unstructured":"Santen, R. J., Yue, W. & Heitjan, D. F. Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy. Cancer Epidemiol. Biomark. Prev. 21, 1038\u20131048 (2012).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"70683_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/path.4288","volume":"232","author":"MC Cummings","year":"2014","unstructured":"Cummings, M. C. et al. Metastatic progression of breast cancer: insights from 50\u2009years of autopsies. J. Pathol. 232, 23\u201331 (2014).","journal-title":"J. Pathol."},{"key":"70683_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ccell.2016.02.002","volume":"29","author":"G Sflomos","year":"2016","unstructured":"Sflomos, G. et al. A preclinical model for ER\u03b1-positive breast cancer points to the epithelial microenvironment as determinant of luminal phenotype and hormone response. Cancer Cell 29, 407\u2013422 (2016).","journal-title":"Cancer Cell"},{"key":"70683_CR11","doi-asserted-by":"crossref","unstructured":"Ghosh, D. et al. Senescent mesenchymal stem cells remodel extracellular matrix driving breast cancer cells to a more-invasive phenotype. J. Cell Sci. 133, jcs232470 (2020).","DOI":"10.1242\/jcs.232470"},{"key":"70683_CR12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41581-022-00601-z","volume":"18","author":"W Huang","year":"2022","unstructured":"Huang, W., Hickson, L. J., Eirin, A., Kirkland, J. L. & Lerman, L. O. Cellular senescence: the good, the bad and the unknown. Nat. Rev. Nephrol. 18, 611\u2013627 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"70683_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11721-9","volume":"10","author":"SP Hong","year":"2019","unstructured":"Hong, S. P. et al. Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy. Nat. Commun. 10, 3840 (2019).","journal-title":"Nat. Commun."},{"key":"70683_CR14","doi-asserted-by":"publisher","first-page":"4623","DOI":"10.1128\/MCB.00269-09","volume":"29","author":"CE Caldon","year":"2009","unstructured":"Caldon, C. E. et al. Estrogen regulation of cyclin E2 requires cyclin D1, but not c-Myc. Mol. Cell Biol. 29, 4623\u20134639 (2009).","journal-title":"Mol. Cell Biol."},{"key":"70683_CR15","doi-asserted-by":"publisher","first-page":"e2987","DOI":"10.1371\/journal.pone.0002987","volume":"3","author":"EA Musgrove","year":"2008","unstructured":"Musgrove, E. A. et al. Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS ONE 3, e2987 (2008).","journal-title":"PLoS ONE"},{"key":"70683_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nbt.2859","volume":"32","author":"C Trapnell","year":"2014","unstructured":"Trapnell, C. et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat. Biotechnol. 32, 381\u2013386 (2014).","journal-title":"Nat. Biotechnol."},{"key":"70683_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/acel.12287","volume":"14","author":"DV Ziegler","year":"2015","unstructured":"Ziegler, D. V., Wiley, C. D. & Velarde, M. C. Mitochondrial effectors of cellular senescence: beyond the free radical theory of aging. Aging Cell 14, 1\u20137 (2015).","journal-title":"Aging Cell"},{"key":"70683_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1083\/jcb.201608026","volume":"215","author":"KM Aird","year":"2016","unstructured":"Aird, K. M. et al. HMGB2 orchestrates the chromatin landscape of senescence-associated secretory phenotype gene loci. J. Cell Biol. 215, 325\u2013334 (2016).","journal-title":"J. Cell Biol."},{"key":"70683_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.molcel.2014.05.003","volume":"55","author":"Y Johmura","year":"2014","unstructured":"Johmura, Y. et al. Necessary and sufficient role for a mitosis skip in senescence induction. Mol. Cell 55, 73\u201384 (2014).","journal-title":"Mol. Cell"},{"key":"70683_CR20","doi-asserted-by":"crossref","unstructured":"Martini H. & Passos J. F. Cellular senescence: all roads lead to mitochondria. FEBS J. 290, 1186\u20131202 (2023).","DOI":"10.1111\/febs.16361"},{"key":"70683_CR21","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/s41388-019-1064-3","volume":"39","author":"ME Clements","year":"2020","unstructured":"Clements, M. E. & Johnson, R. W. PREX1 drives spontaneous bone dissemination of ER+ breast cancer cells. Oncogene 39, 1318\u20131334 (2020).","journal-title":"Oncogene"},{"key":"70683_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215882","volume":"548","author":"S Hareendran","year":"2022","unstructured":"Hareendran, S., Yang, X., Sharma, V. K. & Loh, Y. P. Carboxypeptidase E and its splice variants: key regulators of growth and metastasis in multiple cancer types. Cancer Lett. 548, 215882 (2022).","journal-title":"Cancer Lett."},{"key":"70683_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jbo.2018.09.006","volume":"13","author":"D Wang","year":"2018","unstructured":"Wang, D. et al. NPNT promotes early-stage bone metastases in breast cancer by regulation of the osteogenic niche. J. Bone Oncol. 13, 91\u201396 (2018).","journal-title":"J. Bone Oncol."},{"key":"70683_CR24","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1038\/s41588-018-0252-3","volume":"50","author":"J Kim","year":"2018","unstructured":"Kim, J. et al. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat. Genet. 50, 1705\u20131715 (2018).","journal-title":"Nat. Genet."},{"key":"70683_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102076","volume":"49","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Effect of tumor-derived extracellular vesicle-shuttled lncRNA MALAT1 on proliferation, invasion and metastasis of triple-negative breast cancer by regulating macrophage M2 polarization via the POSTN\/Hippo\/YAP axis. Transl. Oncol. 49, 102076 (2024).","journal-title":"Transl. Oncol."},{"key":"70683_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-022-01503-5","volume":"24","author":"Q Ren","year":"2022","unstructured":"Ren, Q. et al. Gene expression predicts dormant metastatic breast cancer cell phenotype. Breast Cancer Res. 24, 10 (2022).","journal-title":"Breast Cancer Res."},{"key":"70683_CR27","doi-asserted-by":"publisher","first-page":"W234","DOI":"10.1093\/nar\/gkz240","volume":"47","author":"G Zhou","year":"2019","unstructured":"Zhou, G. et al. NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis. Nucleic Acids Res. 47, W234\u2013W241 (2019).","journal-title":"Nucleic Acids Res."},{"key":"70683_CR28","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1158\/1541-7786.MCR-15-0423","volume":"14","author":"L Malorni","year":"2016","unstructured":"Malorni, L. et al. Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol. Cancer Res. 14, 470\u2013481 (2016).","journal-title":"Mol. Cancer Res."},{"key":"70683_CR29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2113527118","volume":"118","author":"N Sabherwal","year":"2021","unstructured":"Sabherwal, N. et al. Differential phase register of Hes1 oscillations with mitoses underlies cell-cycle heterogeneity in ER+ breast cancer cells. Proc. Natl. Acad. Sci. USA 118, e2113527118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"70683_CR30","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1158\/1078-0432.CCR-10-2567","volume":"17","author":"TW Miller","year":"2011","unstructured":"Miller, T. W. et al. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. Clin. Cancer Res. 17, 2024\u20132034 (2011).","journal-title":"Clin. Cancer Res."},{"key":"70683_CR31","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.cellsig.2016.12.002","volume":"30","author":"N Gonzalez","year":"2017","unstructured":"Gonzalez, N. et al. Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells. Cell Signal. 30, 154\u2013161 (2017).","journal-title":"Cell Signal."},{"key":"70683_CR32","doi-asserted-by":"publisher","first-page":"7869","DOI":"10.1073\/pnas.1722617115","volume":"115","author":"T Xiao","year":"2018","unstructured":"Xiao, T. et al. Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy. Proc. Natl. Acad. Sci. USA 115, 7869\u20137878 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"70683_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1560","volume":"2","author":"CR Lindsay","year":"2011","unstructured":"Lindsay, C. R. et al. P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. Nat. Commun. 2, 555 (2011).","journal-title":"Nat. Commun."},{"key":"70683_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10664","volume":"7","author":"H Marei","year":"2016","unstructured":"Marei, H. et al. Differential Rac1 signalling by guanine nucleotide exchange factors implicates FLII in regulating Rac1-driven cell migration. Nat. Commun. 7, 10664 (2016).","journal-title":"Nat. Commun."},{"key":"70683_CR35","doi-asserted-by":"publisher","first-page":"17258","DOI":"10.1074\/jbc.M116.743401","volume":"291","author":"HJ Liu","year":"2016","unstructured":"Liu, H. J. et al. PtdIns(3,4,5)P3-dependent Rac Exchanger 1 (PREX1) Rac-Guanine Nucleotide Exchange Factor (GEF) activity promotes breast cancer cell proliferation and tumor growth via activation of extracellular signal-regulated kinase 1\/2 (ERK1\/2) Signaling. J. Biol. Chem. 291, 17258\u201317270 (2016).","journal-title":"J. Biol. Chem."},{"key":"70683_CR36","doi-asserted-by":"publisher","first-page":"e996016","DOI":"10.1080\/23723556.2014.996016","volume":"2","author":"LM Dillon","year":"2015","unstructured":"Dillon, L. M. & Miller, T. W. The PREX1\/Rac signaling axis: potential as a biomarker and therapeutic target in breast cancer. Mol. Cell. Oncol. 2, e996016 (2015).","journal-title":"Mol. Cell. Oncol."},{"key":"70683_CR37","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.1038\/onc.2014.328","volume":"34","author":"LM Dillon","year":"2015","unstructured":"Dillon, L. M. et al. P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K\/AKT and MEK\/ERK signaling in breast cancer. Oncogene 34, 3968\u20133976 (2015).","journal-title":"Oncogene"},{"key":"70683_CR38","doi-asserted-by":"publisher","first-page":"21124","DOI":"10.1073\/pnas.1314124110","volume":"110","author":"H Ebi","year":"2013","unstructured":"Ebi, H. et al. PI3K regulates MEK\/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Proc. Natl. Acad. Sci. USA 110, 21124\u201321129 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"70683_CR39","doi-asserted-by":"publisher","first-page":"28612","DOI":"10.18632\/oncotarget.25584","volume":"9","author":"L Barrio-Real","year":"2018","unstructured":"Barrio-Real, L. et al. P-Rex1 is dispensable for Erk activation and mitogenesis in breast cancer. Oncotarget 9, 28612\u201328624 (2018).","journal-title":"Oncotarget"},{"key":"70683_CR40","doi-asserted-by":"publisher","first-page":"OT-18-01","DOI":"10.1158\/1538-7445.SABCS20-OT-18-01","volume":"81","author":"N Wagle","year":"2021","unstructured":"Wagle, N. et al. Abstract OT-18-01: the metastatic breast cancer project: generating the clinical and genomic landscape of metastatic breast cancer through patient-partnered research. Cancer Res. 81, OT-18-01\u2013OT-18-01 (2021).","journal-title":"Cancer Res."},{"key":"70683_CR41","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41388-020-01560-0","volume":"40","author":"S Attalla","year":"2021","unstructured":"Attalla, S., Taifour, T., Bui, T. & Muller, W. Insights from transgenic mouse models of PyMT-induced breast cancer: recapitulating human breast cancer progression in vivo. Oncogene 40, 475\u2013491 (2021).","journal-title":"Oncogene"},{"key":"70683_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109689","volume":"36","author":"A Floerchinger","year":"2021","unstructured":"Floerchinger, A. et al. Optimizing metastatic-cascade-dependent Rac1 targeting in breast cancer: guidance using optical window intravital FRET imaging. Cell Rep. 36, 109689 (2021).","journal-title":"Cell Rep."},{"key":"70683_CR43","doi-asserted-by":"publisher","first-page":"e58183","DOI":"10.1371\/journal.pone.0058183","volume":"8","author":"C Franci","year":"2013","unstructured":"Franci, C. et al. Biomarkers of residual disease, disseminated tumor cells, and metastases in the MMTV-PyMT breast cancer model. PLoS ONE 8, e58183 (2013).","journal-title":"PLoS ONE"},{"key":"70683_CR44","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.1128\/MCB.22.18.6582-6591.2002","volume":"22","author":"RE Itoh","year":"2002","unstructured":"Itoh, R. E. et al. Activation of Rac and Cdc42 video imaged by fluorescent resonance energy transfer-based single-molecule probes in the membrane of living cells. Mol. Cell Biol. 22, 6582\u20136591 (2002).","journal-title":"Mol. Cell Biol."},{"key":"70683_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202002518","volume":"7","author":"Y Gao","year":"2020","unstructured":"Gao, Y. et al. CD63+ cancer-associated fibroblasts confer tamoxifen resistance to breast cancer cells through exosomal miR-22. Adv. Sci. 7, 2002518 (2020).","journal-title":"Adv. Sci."},{"key":"70683_CR46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cjp2.118","volume":"5","author":"JR Kutasovic","year":"2019","unstructured":"Kutasovic, J. R. et al. Breast cancer metastasis to gynaecological organs: a clinico-pathological and molecular profiling study. J. Pathol. Clin. Res. 5, 25\u201339 (2019).","journal-title":"J. Pathol. Clin. Res."},{"key":"70683_CR47","doi-asserted-by":"publisher","first-page":"7618","DOI":"10.1073\/pnas.0307512101","volume":"101","author":"Y Gao","year":"2004","unstructured":"Gao, Y., Dickerson, J. B., Guo, F., Zheng, J. & Zheng, Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc. Natl. Acad. Sci. USA 101, 7618\u20137623 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"70683_CR48","doi-asserted-by":"publisher","first-page":"840","DOI":"10.2174\/18715206113136660334","volume":"14","author":"GA Cardama","year":"2014","unstructured":"Cardama, G. A. et al. Preclinical development of novel Rac1-GEF signaling inhibitors using a rational design approach in highly aggressive breast cancer cell lines. Anticancer Agents Med. Chem. 14, 840\u2013851 (2014).","journal-title":"Anticancer Agents Med. Chem."},{"key":"70683_CR49","doi-asserted-by":"publisher","first-page":"e0142182","DOI":"10.1371\/journal.pone.0142182","volume":"10","author":"TI Oprea","year":"2015","unstructured":"Oprea, T. I. et al. Novel activities of Select NSAID R-Enantiomers against Rac1 and Cdc42 GTPases. PLoS ONE 10, e0142182\u2013e0142182 (2015).","journal-title":"PLoS ONE"},{"key":"70683_CR50","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-15-0461","volume":"21","author":"Y Guo","year":"2015","unstructured":"Guo, Y. et al. A novel pharmacologic activity of ketorolac for therapeutic benefit in ovarian cancer patients. Clin. Cancer Res. 21, 5064\u20135072 (2015).","journal-title":"Clin. Cancer Res."},{"key":"70683_CR51","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01133-8","volume":"23","author":"S Shaji","year":"2021","unstructured":"Shaji, S., Smith, C. & Forget, P. Perioperative NSAIDs and long-term outcomes after cancer surgery: a systematic review and meta-analysis. Curr. Oncol. Rep. 23, 146 (2021).","journal-title":"Curr. Oncol. Rep."},{"key":"70683_CR52","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41571-018-0145-5","volume":"16","author":"J Richman","year":"2019","unstructured":"Richman, J. & Dowsett, M. Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer. Nat. Rev. Clin. Oncol. 16, 296\u2013311 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"70683_CR53","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1038\/bjc.2013.671","volume":"109","author":"P Dubsky","year":"2013","unstructured":"Dubsky, P. et al. The EndoPredict score provides prognostic information on late distant metastases in ER+\/HER2\u2212 breast cancer patients. Br. J. Cancer 109, 2959\u20132964 (2013).","journal-title":"Br. J. Cancer"},{"key":"70683_CR54","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.11.011","volume":"72","author":"H-O Adami","year":"2017","unstructured":"Adami, H.-O. et al. Are rapidly growing cancers more lethal? Eur. J. Cancer 72, 210\u2013214 (2017).","journal-title":"Eur. J. Cancer"},{"key":"70683_CR55","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/s41388-017-0027-9","volume":"37","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. IGF1R signaling drives antiestrogen resistance through PAK2\/PIX activation in luminal breast cancer. Oncogene 37, 1869\u20131884 (2018).","journal-title":"Oncogene"},{"key":"70683_CR56","first-page":"207","volume":"18","author":"AE Rosenblatt","year":"2011","unstructured":"Rosenblatt, A. E. et al. Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer. Endocr. Relat. Cancer 18, 207\u2013219 (2011).","journal-title":"Endocr. Relat. Cancer"},{"key":"70683_CR57","first-page":"6802","volume":"63","author":"D Cai","year":"2003","unstructured":"Cai, D. et al. AND-34\/BCAR3, a GDP exchange factor whose overexpression confers antiestrogen resistance, activates Rac, PAK1, and the Cyclin D1 Promoter1. Cancer Res. 63, 6802\u20136808 (2003).","journal-title":"Cancer Res."},{"key":"70683_CR58","doi-asserted-by":"publisher","first-page":"9557","DOI":"10.1093\/nar\/gkz675","volume":"47","author":"G Korkmaz","year":"2019","unstructured":"Korkmaz, G. et al. A CRISPR-Cas9 screen identifies essential CTCF anchor sites for estrogen receptor-driven breast cancer cell proliferation. Nucleic Acids Res. 47, 9557\u20139572 (2019).","journal-title":"Nucleic Acids Res."},{"key":"70683_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-014-0441-7","volume":"16","author":"L Barrio-Real","year":"2014","unstructured":"Barrio-Real, L. et al. Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation. Breast Cancer Res. 16, 441 (2014).","journal-title":"Breast Cancer Res."},{"key":"70683_CR60","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.molcel.2010.11.029","volume":"40","author":"MS Sosa","year":"2010","unstructured":"Sosa, M. S. et al. Identification of the Rac-GEF P-Rex1 as an Essential Mediator of ErbB signaling in Breast Cancer. Mol. Cell 40, 877\u2013892 (2010).","journal-title":"Mol. Cell"},{"key":"70683_CR61","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/onc.2010.489","volume":"30","author":"JC Montero","year":"2011","unstructured":"Montero, J. C., Seoane, S., Oca\u00f1a, A. & Pandiella, A. P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer. Oncogene 30, 1059\u20131071 (2011).","journal-title":"Oncogene"},{"key":"70683_CR62","doi-asserted-by":"publisher","first-page":"28056","DOI":"10.1073\/pnas.2006445117","volume":"117","author":"N Srijakotre","year":"2020","unstructured":"Srijakotre, N. et al. PtdIns(3,4,5)P3-dependent Rac exchanger 1 (P-Rex1) promotes mammary tumor initiation and metastasis. Proc. Natl. Acad. Sci. USA 117, 28056\u201328067 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"70683_CR63","doi-asserted-by":"publisher","first-page":"6554","DOI":"10.12659\/MSM.915845","volume":"25","author":"Y Zhong","year":"2019","unstructured":"Zhong, Y. et al. Phosphatidylinositol-3,4,5-Trisphosphate Dependent Rac Exchange Factor 1 (PREX1) is a novel predictor of prognosis for breast cancer patients: a retrospective case series. Med. Sci. Monit. 25, 6554\u20136562 (2019).","journal-title":"Med. Sci. Monit."},{"key":"70683_CR64","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ajpath.2017.10.018","volume":"188","author":"AS Peretti","year":"2018","unstructured":"Peretti, A. S. et al. The R-enantiomer of ketorolac delays mammary tumor development in mouse mammary tumor virus-polyoma middle T antigen (MMTV-PyMT) Mice.  Am. J. Pathol. 188, 515\u2013524 (2018).","journal-title":"Am. J. Pathol."},{"key":"70683_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07716-1","volume":"21","author":"MM Grimes","year":"2021","unstructured":"Grimes, M. M. et al. The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo. BMC Cancer 21, 40 (2021).","journal-title":"BMC Cancer"},{"key":"70683_CR66","doi-asserted-by":"publisher","first-page":"e1000438","DOI":"10.1371\/journal.pcbi.1000438","volume":"5","author":"R Samaga","year":"2009","unstructured":"Samaga, R., Saez-Rodriguez, J., Alexopoulos, L. G., Sorger, P. K. & Klamt, S. The logic of EGFR\/ErbB signaling: theoretical properties and analysis of high-throughput data. PLoS Comp. Biol. 5, e1000438 (2009).","journal-title":"PLoS Comp. Biol."},{"key":"70683_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08641-7","volume":"21","author":"SY Moon","year":"2021","unstructured":"Moon, S. Y. et al. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells. BMC Cancer 21, 931 (2021).","journal-title":"BMC Cancer"},{"key":"70683_CR68","doi-asserted-by":"crossref","unstructured":"Takeda, T. et al. EGFR inhibition reverses epithelial\u2011mesenchymal transition, and decreases tamoxifen resistance via Snail and Twist downregulation in breast cancer cells. Oncol. Rep. 47, 109 (2022).","DOI":"10.3892\/or.2022.8320"},{"key":"70683_CR69","doi-asserted-by":"publisher","first-page":"805","DOI":"10.33594\/000000174","volume":"53","author":"Y Jeong","year":"2019","unstructured":"Jeong, Y. et al. EGFR is a therapeutic target in hormone receptor-positive breast cancer. Cell Physiol. Biochem. 53, 805\u2013819 (2019).","journal-title":"Cell Physiol. Biochem."},{"key":"70683_CR70","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1210\/en.2002-220620","volume":"144","author":"JM Knowlden","year":"2003","unstructured":"Knowlden, J. M. et al. Elevated levels of epidermal growth factor receptor\/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144, 1032\u20131044 (2003).","journal-title":"Endocrinology"},{"key":"70683_CR71","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1073\/pnas.1018859108","volume":"109","author":"K Jin","year":"2012","unstructured":"Jin, K. et al. The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proc. Natl. Acad. Sci. USA 109, 2736\u20132741 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"70683_CR72","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1158\/1535-7163.MCT-15-0548-T","volume":"15","author":"JP De Andrade","year":"2016","unstructured":"De Andrade, J. P. et al. EGFR is regulated by TFAP2C in luminal breast cancer and is a target for vandetanib. Mol. Cancer Ther. 15, 503\u2013511 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"70683_CR73","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/annonc\/mdl016","volume":"17","author":"M Dowsett","year":"2006","unstructured":"Dowsett, M. et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann. Oncol. 17, 818\u2013826 (2006).","journal-title":"Ann. Oncol."},{"key":"70683_CR74","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1200\/JCO.2001.19.14.3376","volume":"19","author":"AS Knoop","year":"2001","unstructured":"Knoop, A. S., Bentzen, S. M., Nielsen, M. M., Rasmussen, B. B. & Rose, C. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J. Clin. Oncol. 19, 3376\u20133384 (2001).","journal-title":"J. Clin. Oncol."},{"key":"70683_CR75","first-page":"1039","volume":"9","author":"S De Placido","year":"2003","unstructured":"De Placido, S. et al. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer1. Clin. Cancer Res. 9, 1039\u20131046 (2003).","journal-title":"Clin. Cancer Res."},{"key":"70683_CR76","doi-asserted-by":"publisher","first-page":"e22613","DOI":"10.1097\/MD.0000000000022613","volume":"99","author":"J Ye","year":"2020","unstructured":"Ye, J., Tian, T. & Chen, X. The efficacy of gefitinib supplementation for breast cancer: a meta-analysis of randomized controlled studies. Medicine 99, e22613 (2020).","journal-title":"Medicine"},{"key":"70683_CR77","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/annonc\/mdp202","volume":"20","author":"MD Green","year":"2009","unstructured":"Green, M. D. et al. Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. Ann. Oncol. 20, 1813\u20131817 (2009).","journal-title":"Ann. Oncol."},{"key":"70683_CR78","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s10549-012-1997-5","volume":"133","author":"RW Carlson","year":"2012","unstructured":"Carlson, R. W. et al. A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer. Breast Cancer Res. Treat. 133, 1049\u20131056 (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"70683_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/sigtrans.2016.42","volume":"2","author":"R Ali","year":"2017","unstructured":"Ali, R. & Wendt, M. K. The paradoxical functions of EGFR during breast cancer progression. Signal Transduct. Target. Ther. 2, 16042 (2017).","journal-title":"Signal Transduct. Target. Ther."},{"key":"70683_CR80","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1158\/1541-7786.MCR-21-0038","volume":"20","author":"C Leonce","year":"2022","unstructured":"Leonce, C., Saintigny, P. & Ortiz-Cuaran, S. Cell-intrinsic mechanisms of drug tolerance to systemic therapies in cancer. Mol. Cancer Res. 20, 11\u201329 (2022).","journal-title":"Mol. Cancer Res."},{"key":"70683_CR81","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1111\/febs.15282","volume":"287","author":"N Levi","year":"2020","unstructured":"Levi, N., Papismadov, N., Solomonov, I., Sagi, I. & Krizhanovsky, V. The ECM path of senescence in aging: components and modifiers.  FEBS J. 287, 2636\u20132646 (2020).","journal-title":"FEBS J."},{"key":"70683_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00347-0","volume":"7","author":"C Prunier","year":"2021","unstructured":"Prunier, C. et al. Breast cancer dormancy is associated with a 4NG1 state and not senescence. npj Breast Cancer 7, 140 (2021).","journal-title":"npj Breast Cancer"},{"key":"70683_CR83","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/j.1349-7006.2009.01151.x","volume":"100","author":"K Morimoto","year":"2009","unstructured":"Morimoto, K. et al. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci. 100, 1062\u20131068 (2009).","journal-title":"Cancer Sci."},{"key":"70683_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32523-6","volume":"13","author":"P Aouad","year":"2022","unstructured":"Aouad, P. et al. Epithelial-mesenchymal plasticity determines estrogen receptor positive breast cancer dormancy and epithelial reconversion drives recurrence. Nat. Commun. 13, 4975 (2022).","journal-title":"Nat. Commun."},{"key":"70683_CR85","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ejca.2013.10.004","volume":"50","author":"G Aurilio","year":"2014","unstructured":"Aurilio, G. et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur. J. Cancer 50, 277\u2013289 (2014).","journal-title":"Eur. J. Cancer"},{"key":"70683_CR86","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-9-131","volume":"9","author":"R Nishimura","year":"2011","unstructured":"Nishimura, R. et al. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World J. Surg. Oncol. 9, 131 (2011).","journal-title":"World J. Surg. Oncol."},{"key":"70683_CR87","first-page":"139","volume":"42","author":"RL Eckert","year":"1982","unstructured":"Eckert, R. L. & Katzenellenbogen, B. S. Effects of estrogens and antiestrogens on estrogen receptor dynamics and the induction of progesterone receptor in MCF-7 human breast cancer cells. Cancer Res. 42, 139\u2013144 (1982).","journal-title":"Cancer Res."},{"key":"70683_CR88","doi-asserted-by":"crossref","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","DOI":"10.1038\/nmeth.2019"},{"key":"70683_CR89","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.53367","volume":"9","author":"JF Hastings","year":"2020","unstructured":"Hastings, J. F. et al. Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma. Elife 9, e53367 (2020).","journal-title":"Elife"},{"key":"70683_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-016-0781-6","volume":"18","author":"AIJ Young","year":"2016","unstructured":"Young, A. I. J. et al. MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib. Breast Cancer Res. 18, 125 (2016).","journal-title":"Breast Cancer Res."},{"key":"70683_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2358","volume":"11","author":"F Behbod","year":"2009","unstructured":"Behbod, F. et al. An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res. 11, R66 (2009).","journal-title":"Breast Cancer Res."},{"key":"70683_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"70683_CR93","doi-asserted-by":"publisher","first-page":"eabh0363","DOI":"10.1126\/sciadv.abh0363","volume":"7","author":"KJ Murphy","year":"2021","unstructured":"Murphy, K. J. et al. Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. Sci. Adv. 7, eabh0363\u2013eabh0363 (2021).","journal-title":"Sci. Adv."},{"key":"70683_CR94","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1073\/pnas.1104778108","volume":"109","author":"SR Oakes","year":"2012","unstructured":"Oakes, S. R. et al. Sensitization of BCL-2\u2013expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc. Natl. Acad. Sci. USA 109, 2766\u20132771 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"70683_CR95","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.cell.2015.05.002","volume":"161","author":"EvanZ Macosko","year":"2015","unstructured":"Macosko, E. vanZ. et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell 161, 1202\u20131214 (2015).","journal-title":"Cell"},{"key":"70683_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108945","volume":"35","author":"F Vald\u00e9s-Mora","year":"2021","unstructured":"Vald\u00e9s-Mora, F. et al. Single-cell transcriptomics reveals involution mimicry during the specification of the basal breast cancer subtype. Cell Rep. 35, 108945 (2021).","journal-title":"Cell Rep."},{"key":"70683_CR97","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/nbt.1883","volume":"29","author":"MG Grabherr","year":"2011","unstructured":"Grabherr, M. G. et al. Full-length transcriptome assembly from RNA-Seq data without a reference genome. Nat. Biotechnol. 29, 644\u2013652 (2011).","journal-title":"Nat. Biotechnol."},{"key":"70683_CR98","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"70683_CR99","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nature20123","volume":"539","author":"I Tirosh","year":"2016","unstructured":"Tirosh, I. et al. Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature 539, 309\u2013313 (2016).","journal-title":"Nature"},{"key":"70683_CR100","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"70683_CR101","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha, V. K. et al. PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267\u2013273 (2003).","journal-title":"Nat. Genet."},{"key":"70683_CR102","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1093\/bioinformatics\/btz931","volume":"36","author":"SX Ge","year":"2019","unstructured":"Ge, S. X., Jung, D. & Yao, R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. Bioinformatics 36, 2628\u20132629 (2019).","journal-title":"Bioinformatics"},{"key":"70683_CR103","first-page":"D504","volume":"48","author":"L Licata","year":"2020","unstructured":"Licata, L. et al. SIGNOR 2.0, the SIGnaling Network Open Resource 2.0: 2019 update. Nucleic Acids Res. 48, D504\u2013d510 (2020).","journal-title":"Nucleic Acids Res."},{"key":"70683_CR104","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nprot.2015.052","volume":"10","author":"J Xia","year":"2015","unstructured":"Xia, J., Gill, E. E. & Hancock, R. E. NetworkAnalyst for statistical, visual and network-based meta-analysis of gene expression data. Nat. Protoc. 10, 823\u2013844 (2015).","journal-title":"Nat. Protoc."},{"key":"70683_CR105","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.celrep.2017.09.022","volume":"21","author":"M Nobis","year":"2017","unstructured":"Nobis, M. et al. A RhoA-FRET biosensor mouse for intravital imaging in normal tissue homeostasis and disease contexts. Cell Rep. 21, 274\u2013288 (2017).","journal-title":"Cell Rep."},{"key":"70683_CR106","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/nmeth.1269","volume":"5","author":"D Kedrin","year":"2008","unstructured":"Kedrin, D. et al. Intravital imaging of metastatic behavior through a mammary imaging window. Nat. Methods 5, 1019\u20131021 (2008).","journal-title":"Nat. Methods"},{"key":"70683_CR107","first-page":"553","volume":"52","author":"JC Ingrao","year":"2013","unstructured":"Ingrao, J. C. et al. Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL\/6 mice. J. Am. Assoc. Lab Anim. Sci. 52, 553\u2013559 (2013).","journal-title":"J. Am. Assoc. Lab Anim. Sci."},{"key":"70683_CR108","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.35800","volume":"7","author":"SC Warren","year":"2018","unstructured":"Warren, S. C. et al. Removing physiological motion from intravital and clinical functional imaging data. Elife 7, e35800 (2018).","journal-title":"Elife"},{"key":"70683_CR109","unstructured":"Stenger, M. Calculating H-Score. The ASCO Post https:\/\/ascopost.com\/issues\/july-10-2015\/calculating-h-score\/ (2015)."},{"key":"70683_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11049-4","volume":"10","author":"M Singh","year":"2019","unstructured":"Singh, M. et al. High-throughput targeted long-read single cell sequencing reveals the clonal and transcriptional landscape of lymphocytes. Nat. Commun. 10, 3120 (2019).","journal-title":"Nat. Commun."},{"key":"70683_CR111","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1038\/nm.2454","volume":"17","author":"YS DeRose","year":"2011","unstructured":"DeRose, Y. S. et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 17, 1514 (2011).","journal-title":"Nat. Med."},{"key":"70683_CR112","doi-asserted-by":"crossref","unstructured":"Chia, K. et al. Non-canonical AR activity facilitates endocrine resistance in breast cancer. 26, 251 (2019).","DOI":"10.1530\/ERC-18-0333"},{"key":"70683_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25422-9","volume":"12","author":"CL Alves","year":"2021","unstructured":"Alves, C. L. et al. Co-targeting CDK4\/6 and AKT with endocrine therapy prevents progression in CDK4\/6 inhibitor and endocrine therapy-resistant breast cancer. Nat. Commun. 12, 5112 (2021).","journal-title":"Nat. Commun."},{"key":"70683_CR114","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","volume":"53","author":"SZ Wu","year":"2021","unstructured":"Wu, S. Z. et al. A single-cell and spatially resolved atlas of human breast cancers. Nat. Genet. 53, 1334\u20131347 (2021).","journal-title":"Nat. Genet."},{"key":"70683_CR115","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10549-009-0674-9","volume":"123","author":"B Gy\u00f6rffy","year":"2010","unstructured":"Gy\u00f6rffy, B. et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Res. Treat. 123, 725\u2013731 (2010).","journal-title":"Breast Cancer Res. Treat."},{"key":"70683_CR116","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1158\/0008-5472.CAN-17-0369","volume":"77","author":"J Li","year":"2017","unstructured":"Li, J. et al. Explore, visualize, and analyze functional cancer proteomic data using the cancer proteome Atlas. Cancer Res. 77, e51\u2013e54 (2017).","journal-title":"Cancer Res."},{"key":"70683_CR117","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/nmeth.2650","volume":"10","author":"J Li","year":"2013","unstructured":"Li, J. et al. TCPA: a resource for cancer functional proteomics data. Nat. Methods 10, 1046\u20131047 (2013).","journal-title":"Nat. Methods"},{"key":"70683_CR118","doi-asserted-by":"crossref","unstructured":"Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346\u2013352 (2012).","DOI":"10.1038\/nature10983"},{"key":"70683_CR119","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"70683_CR120","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1\u2013pl1 (2013).","journal-title":"Sci. Signal."},{"key":"70683_CR121","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30342-3","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y., Chen, F., Chandrashekar, D. S., Varambally, S. & Creighton, C. J. Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways. Nat. Commun. 13, 2669 (2022).","journal-title":"Nat. Commun."},{"key":"70683_CR122","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neo.2022.01.001","volume":"25","author":"DS Chandrashekar","year":"2022","unstructured":"Chandrashekar, D. S. et al. UALCAN: an update to the integrated cancer data analysis platform. Neoplasia 25, 18\u201327 (2022).","journal-title":"Neoplasia"},{"key":"70683_CR123","doi-asserted-by":"publisher","first-page":"D991","DOI":"10.1093\/nar\/gks1193","volume":"41","author":"T Barrett","year":"2012","unstructured":"Barrett, T. et al. NCBI GEO: archive for functional genomics data sets\u2014update. Nucleic Acids Res. 41, D991\u2013D995 (2012).","journal-title":"Nucleic Acids Res."},{"key":"70683_CR124","doi-asserted-by":"publisher","first-page":"W207","DOI":"10.1093\/nar\/gkad347","volume":"51","author":"L Kolberg","year":"2023","unstructured":"Kolberg, L. et al. g:Profiler-interoperable web service for functional enrichment analysis and gene identifier mapping (2023 update). Nucleic Acids Res. 51, W207\u2013w212 (2023).","journal-title":"Nucleic Acids Res."},{"key":"70683_CR125","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1177\/1536867X0400400204","volume":"4","author":"JAC Sterne","year":"2004","unstructured":"Sterne, J. A. C. & Harbord, R. M. Funnel plots in meta-analysis. Stat J. 4, 127\u2013141 (2004).","journal-title":"Stat J."},{"key":"70683_CR126","unstructured":"Review Manager (RevMan) Version 5.4. The Cochrane Collaboration (2020)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70683-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70683-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70683-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T09:11:44Z","timestamp":1778490704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70683-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":126,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["70683"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-70683-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"11 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3042"}}